Sanofi - ADR
SNY
Market Cap$123.17B
Close$
Earnings Call Q4 2023
February 1, 2024 - AI Summary
Sanofi reported strong Q4 and full-year 2023 results, driven by the performance of Dupixent and key launches such as Beyfortus.
Dupixent sales reached almost EUR3 billion in Q4 alone, with full-year sales up 34%. The company expects Dupixent to reach around EUR13 billion in sales in 2024.
Beyfortus had a successful launch, with record uptake and sales of over EUR400 million in Q4. Supply is being expanded to meet demand, and the vaccine is expected to reach blockbuster status in 2024.
Exclusive for Stockcircle Pro members
Sign up
$140.19
186% upside
Current Fair Value
186% upsideUndervalued by 186% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $123.17 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $3.8602 (7.93%) |
| Earnings per Share | $2.38 |
| Beta | 0.25 |
| Outstanding Shares | 2,529,606,602 |
| Avg 30 Day Volume | 2,492,548 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 20.63 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Sanofi
CEO: Paul Hudson Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the c...